Recent Updates

Modified on: 
Apr 15, 2021

Whole blood donations are separated into specific cellular (red blood cells and platelets) and plasma components. Transfusing the appropriate blood component to effectively provide for the clinical needs of patients optimizes use of donated blood.

This chapter describes the manufacturing process for the most commonly prepared blood components:

  • Red blood cells (RBC)
  • Platelets: pooled and apheresis
  • Frozen plasma (FP)
  • Apheresis fresh frozen plasma (AFFP)
  • Cryosupernatant plasma (CSP)
  • Cryoprecipitate
Transfusion
Modified on: 
Apr 14, 2021

A. Reporting

Attention: All transfusion reactions (mild to life-threatening) and transfusion-related errors must be reported to the hospital’s transfusion service (blood bank).

What:

Transfusion
Modified on: 
Apr 13, 2021

All blood transfused in Canada is collected from volunteer donors. To ensure the safety of blood components, donors are carefully screened. In addition, the donated blood is tested to identify blood group, blood group antibodies and transfusion-transmissible pathogens. Donor eligibility criteria and testing also benefit the donors by reducing potential blood donation-related health risks.

This chapter describes the donor selection process, the testing done on donated blood, and the pathogen inactivation processes that can further reduce risk of transfusion-transmitted diseases. This chapter is complemented by Chapter 7, Fractionated Blood products and Associated Pathogen Safety, and Chapter 8, Pre-transfusion Testing, of this Guide.

Transfusion
Modified on: 
Apr 7, 2021

The content on this page is specific for 2020-2021 Transfusion Camp. Content for 2021-2022 will start being updated approximately one month ahead of the live event held in Toronto. See General Information Schedules and Locations document for live event dates.

Reminder:

Transfusion
Modified on: 
Apr 6, 2021

Modified or specialty blood components may be useful in specific clinical settings to reduce the risk of transfusion-related harm. This chapter describes the preparation of irradiated, washed, and CMV seronegative cellular blood components (red blood cells and platelets) and the clinical setting in which they are of greatest benefit.

Transfusion
Modified on: 
Apr 1, 2021

http://cancovid19plasma.ca/This repository aims to support Canadian transfusion medicine health care professionals during the COVID-19 pandemic. It will be updated regularly as new information is available. In addition, the public and donors can learn more about how Canadian Blood Services is responding to COVID-19 by visiting blood.ca/covid-19.

Transfusion
Modified on: 
Mar 23, 2021

Authors: Aditi Khandelwal, MDCM, FRCPC; Sandra Ramirez-Arcos, MSc, PhD; and Mark Bigham, MD, MHSc, FRCPC
Publication date: March 2021
Primary target audiences: Medical laboratory technologists (MLTs) in a hospital laboratory, transfusion medicine physicians

Transfusion
Modified on: 
Mar 12, 2021

The content on this page is specific for 2020-2021 Transfusion Camp. Content for 2021-2022 will start being updated approximately one month ahead of the live event held in Toronto. See General Information Schedules and Locations document for live event dates.

Transfusion
Modified on: 
Mar 12, 2021

The content on this page is specific for 2020-21 Transfusion Camp. Content for 2021-2022 will start being updated approximately one month ahead of the live event held in Toronto. See General Information Schedules and Locations document for live event dates.

Reminder:

Transfusion
Modified on: 
Mar 12, 2021

The content on this page is specific for 2020-2021 Transfusion Camp. Content for 2021-2022 will start being updated approximately one month ahead of the live event held in Toronto. See General Information Schedules and Locations document for live event dates.

Reminder:

Transfusion

Pages